Most commonly reported AEs in STS or placebo groups were application site reactions ( STS = 24.3 % ; placebo = 21.8 % ) , headache ( STS = 17.1 % ; placebo = 16.7 % ) , and nausea ( STS = 7.2 % ; placebo = 7.7 % ) .